In the AT-IR subgroup, rates of achieving clinical and endoscopic outcomes were generally higher with either dose of risankizumab versus placebo (withdrawal), regardless of the prior failure to AT number (1, ≥ 2), mechanism of action (TNF inhibitor, vedolizumab, JAK inhibitor), or specific TNF inhibitor type (infliximab, adalimumab, golimumab; Figures 2 and S3). The gene discussed is TNF; the disease is ataxia telangiectasia.